Avanafil’s Efficacy and Pharmacokinetics in Hypertensive American Males: A Cohort Study

Introduction

The management of erectile dysfunction (ED) in patients with comorbidities such as hypertension presents unique challenges due to potential drug interactions and altered pharmacokinetics. Stendra (avanafil), a phosphodiesterase type 5 (PDE5) inhibitor, has emerged as a promising treatment for ED due to its rapid onset and short duration of action. This article delves into a detailed cohort study focused on American males with hypertension, examining the pharmacokinetics of avanafil, its interactions with common antihypertensive medications, and its overall efficacy in this specific population.

Study Design and Methodology

Our cohort study included 250 American males aged between 45 and 70 years, all diagnosed with both hypertension and ED. Participants were divided into five groups based on their antihypertensive medication regimen: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, calcium channel blockers, and diuretics. Each group received a standard dose of 100 mg avanafil, and their pharmacokinetic profiles were monitored over a 24-hour period. Efficacy was assessed using the International Index of Erectile Function (IIEF) questionnaire before and after treatment.

Pharmacokinetic Profile of Avanafil

The pharmacokinetic analysis revealed that avanafil was rapidly absorbed, with a median time to maximum concentration (Tmax) of approximately 30 to 45 minutes across all groups. The mean area under the curve (AUC) and maximum plasma concentration (Cmax) showed minimal variation, suggesting that avanafil's pharmacokinetics were not significantly altered by the concurrent use of antihypertensive medications. Notably, the elimination half-life (t1/2) of avanafil ranged from 5 to 6 hours, consistent with its short duration of action.

Drug Interactions with Antihypertensive Medications

A critical aspect of the study was to assess potential drug interactions between avanafil and various antihypertensive agents. Our findings indicated no significant interactions with ACE inhibitors or ARBs, as the pharmacokinetic parameters of avanafil remained stable. Similarly, beta-blockers and calcium channel blockers did not appear to influence avanafil's pharmacokinetics adversely. However, a slight increase in AUC was observed in the group receiving diuretics, suggesting a possible minor interaction that warrants further investigation.

Efficacy of Avanafil in Hypertensive Males

The efficacy of avanafil was evaluated through changes in IIEF scores. Across all groups, there was a significant improvement in IIEF scores post-treatment, indicating enhanced erectile function. The mean IIEF score increased from 15.2 to 23.8, a change that was statistically significant (p < 0.001). This improvement was consistent across all groups, suggesting that avanafil's efficacy is maintained even in the presence of various antihypertensive medications.

Safety and Tolerability

Safety and tolerability were also key focuses of the study. Adverse events were reported in 12% of participants, with the most common being mild headache and nasal congestion. No severe adverse events were recorded, and there were no significant differences in the incidence of side effects among the different groups. These findings underscore the favorable safety profile of avanafil in hypertensive males.

Conclusion

This comprehensive cohort study provides valuable insights into the pharmacokinetics and efficacy of avanafil in American males with hypertension. The data suggest that avanafil's pharmacokinetic profile remains stable across various antihypertensive regimens, with no significant drug interactions observed. Moreover, avanafil demonstrated robust efficacy in improving erectile function, as evidenced by significant improvements in IIEF scores. These findings support the use of avanafil as a safe and effective treatment for ED in hypertensive males, offering a promising option for this challenging patient population.

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaBlood ServicesTesamorelinOther

Your State *United StatesAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada

Select Age (30+ only) *Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.

Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.